NCT05925764 WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
| NCT ID | NCT05925764 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Condition | Lung Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-10-15 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-10-15 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the performance of a whole slide image based deep learning model for diagnosing the IASLC grading system in resected lung adenocarcinoma based on a multicenter prospective cohort.
Eligibility Criteria
Inclusion Criteria: 1. Age ranging from 18-85 years old; 2. Pathological confirmation of primary lung adenocarcinoma after surgery; 3. Obtained written informed consent. Exclusion Criteria: 1. Multiple lung lesions; 2. Poor quality of whole slide images; 3. Mucinous adenocarcinomas and variants; 4. Participants who have received neoadjuvant therapy.
Frequently Asked Questions
Who can join the NCT05925764 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Lung Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05925764 currently recruiting?
Yes, NCT05925764 is actively recruiting participants. Visit ClinicalTrials.gov or contact Shanghai Pulmonary Hospital, Shanghai, China to inquire about joining.
Where is the NCT05925764 trial being conducted?
This trial is being conducted at Zunyi, China, Nanchang, China, Ningbo, China.
Who is sponsoring the NCT05925764 clinical trial?
NCT05925764 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China. The trial plans to enroll 200 participants.